EGFR and non-small cell lung carcinoma: Afatinib is a second-generation irreversible EGFR-TKI primarily targeting EGFR and human epidermal growth factor receptor 2 (HER2), which may contribute to its mechanism for inducing cardiotoxicity in NSCLC patients [27, 28].